Susquehanna International Group
JUNO

Susquehanna International Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Susquehanna International Group’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-464,800
Closed -$21.2M – 10806
2017
Q4 		$21.2M Buy
464,800
+171,800
+59% +$8.57M 0.01% 1213
2017
Q3 		$13.1M Buy
293,000
+32,300
+12% +$1.1M 0.01% 1552
2017
Q2 		$7.79M Buy
260,700
+112,100
+75% +$2.77M ﹤0.01% 1916
2017
Q1 		$3.3M Sell
148,600
-73,900
-33% -$1.59M ﹤0.01% 2892
2016
Q4 		$4.19M Sell
222,500
-60,300
-21% -$1.48M ﹤0.01% 2713
2016
Q3 		$8.49M Sell
282,800
-38,000
-12% -$1.18M ﹤0.01% 1647
2016
Q2 		$12.3M Sell
320,800
-1,800
-0.6% -$74.7K 0.01% 1287
2016
Q1 		$12.3M Buy
322,600
+210,600
+188% +$7.34M 0.01% 1370
2015
Q4 		$4.92M Sell
112,000
-100,100
-47% -$4.96M ﹤0.01% 2565
2015
Q3 		$8.63M Buy
212,100
+151,500
+250% +$6.64M ﹤0.01% 2001
2015
Q2 		$3.23M Sell
60,600
-47,800
-44% -$2.54M ﹤0.01% 3710
2015
Q1 		$6.58M Buy
+108,400
New +$5.26M ﹤0.01% 2363

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Susquehanna International Group's JUNO Position: Q1 2018 in Review

Susquehanna International Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 352,027 shares — an estimated $16.1M sold.

Susquehanna International Group first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $16.1M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Susquehanna International Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Susquehanna International Group sold 352,027 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $16.1M.
  • Susquehanna International Group first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Susquehanna International Group's Juno Therapeutics, Inc. position peaked at $16.1M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Susquehanna International Group's 13F filing for Q1 2018, filed 15 May 2018.